Covid-19 Long Immunité IMagerie (CLIIM)

Specific Markers of Covid-long Syndrome: Identifying the Mechanisms Involved With a View to Defining Diagnostic Criteria

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06528171

Acronym

CLIIM

Enrollment

200

Registered

2024-07-30

Start date

2024-12-06

Completion date

2028-06-01

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID Long-Haul

Brief summary

Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.

Interventions

PROCEDUREBrain MRI

non injected brain MRI

BIOLOGICALSpecific blood samples

blood samples to find immunological and inflammatory markers

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

FOR CL+ PATIENTS Inclusion Criteria: * Case definition in line with WHO Delphi process

Exclusion criteria

* History of chronic fatigue syndrome diagnosed before or after Covid. * History of progressive psychiatric pathology. * History of acute Covid requiring admission to intensive care and mechanical ventilation. * No social security affiliation. FOR CONTROL (CL-) Inclusion Criteria: * History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion). * Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).

Design outcomes

Primary

Measure	Time frame	Description
Predictive model of Covid-long	24 months	Build and validate a multivariate predictive model of Covid-long considering immunological, inflammatory and brain imaging markers.

Secondary

Measure	Time frame	Description
Evolution of these markers over time	24 months	Comparison of data over time between cohorts (CL+ vs. CL-)

Countries

France

Contacts

CONTACTMichel CARLES, PhD

carles.m@chu-nice.fr04 92 03 55 15

CONTACTIrit TOUITOU

touitou.i@chu-nice.fr04 92 03 58 47

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026